Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Shein Shares Slide 9% in Hong Kong IPO Debut 
RBNZ Raises Interest Rate to 2.75%, Kiwi Dollar Slides 
Asian Stocks Fall as Fed Rate Hike Bets and Iran Conflict Rattle Markets 
Asian Currencies Weaken as Dollar Rises, Kiwi Slides After RBNZ Hike 
Dollar Holds Near Two-Week High as Fed Rate Hike Bets Rise 
Australia GDP Beats Forecast, Boosting RBA Rate Hike Bets 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Brazil, US Resume Tariff Talks as Trade Tensions Persist 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Asian Stocks Slip as Fed Rate Hike Bets and Oil Surge Weigh 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
OpenAI Rejects Apple Trade Secret Theft Claims 
Asian Stocks Tumble as Oil Surge Fuels Rate Hike Fears 
Add as a preferred source on Google
Samsung Biologics revealed on Monday, Sept. 18, that it has closed a contract manufacturing organization deal (CMO) with Bristol-Myers Squibb to produce immunotherapy medications until 2030. The contract is said to be worth $242 million.
Bristol-Myers Squibb is one of the long-term customers of Samsung Biologics, so this is just another deal for a new production request. They have been working together for the CMO business since 2013. In any case, on the part of the Korean biopharmaceutical company, this contract has been added to its streak of wins for CMO projects this year alone.
Collectively, the company is close to hitting the KRW3 trillion or $2.26 billion mark for all of its deals so far in 2023. Reaching this amount is said to be a milestone for Samsung Biologics as it is happening for the first time.
As per The Korea Herald, as of September 2023, the Incheon-based biotechnology firm was able to secure contract manufacturing deals with 14 of the world’s top 20 pharmaceuticals. Novartis and Pfizer are the other major brands that signed large-scale agreements with the company.
Meanwhile, Samsung Biologics agreed to produce immunotherapies of Bristol-Myers Squibb. These will be manufactured in its fourth plant in the span of seven years.
An official of the biotech arm of the Samsung Group said, “Securing the latest deal was possible as Samsung Biologics has proved itself as a reliable contract manufacturer to its global partners, with its large production capacity, fast manufacturing speeds and consistent, high-quality output.”
“Our relationship with Bristol Myers Squibb spans over a decade, and we are proud and excited to help bring important medicines to patients around the world,” Samsung Biologics’ president and chief executive officer, John Rim, further said in a statement. “This collaboration with Bristol Myers Squibb underscores our commitment to expediting the delivery and ensuring the continuous supply of client pipelines, enabled by our commitment to manufacturing quality, innovation, and capacity.”
Photo by: Samsung Biologics Newsroom
